Skip to main content
Category

Research

targeted oncology
Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC ResearchTreatments

Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC

*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had progressed demonstrated a prolonged benefit beyond the initial progression event, according to a retrospective analysis of 118 patients from The University of Texas MD Anderson Cancer Center (MDACC) and the…
laurabbook@gmail.com
February 3, 2019
OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How? ResearchTreatments

OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How?

*November 10, 2018* GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer. Videos from the live webcast: Newer Technologies in Radiation; Novel Indications for Local Therapy in Advanced NSCLC; Systemic Therapies for Advanced NSCLC - Shifting the Utility of Local Therapies; The…
laurabbook@gmail.com
January 5, 2019
Study Shows Key Enzyme Linked to Therapy Resistance in Deadly Lung Cancer ResearchTreatments

Study Shows Key Enzyme Linked to Therapy Resistance in Deadly Lung Cancer

*December 10, 2018, University of Texas M. D. Anderson Cancer Center*  Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and therapy resistance in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). They believe two…
laurabbook@gmail.com
January 4, 2019
Cancer Research UK Tests First of its Kind Vaccine to Treat Lung Cancer ResearchTreatments

Cancer Research UK Tests First of its Kind Vaccine to Treat Lung Cancer

June 12 2018.  A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc. Cancer Research UK will manage the initial clinical development of AST-VAC2, a…
laurabbook@gmail.com
January 4, 2019
PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS ResearchTreatments

PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS

Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived xenograft (PDX) models to help researchers better understand why patients living…
laurabbook@gmail.com
November 22, 2018
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors ResearchTreatments

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an association between selection of EGFR T790M-negative but EGFR G724S-positive subclones and osimertinib resistance.…
laurabbook@gmail.com
November 22, 2018
J&J buys novel lung cancer drug from South Korea’s Yuhan ResearchTreatments

J&J buys novel lung cancer drug from South Korea’s Yuhan

*November 7, 2018* Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC). J&J’s pharma arm, Janssen, struck the deal with South Korea-based Yuhan and has agreed to pay $50m upfront to secure the licence. The move sent…
laurabbook@gmail.com
November 22, 2018
Bring Hope Home Research

Bring Hope Home

June 19th Living Room "Resistance to Targeted Therapy" Dr. Colin Blakely will be discussing all the questions about progression in your lung cancer and where to go and what to do. Dr. Blakely will be talking about what is happening in the research field from next generation therapies after progression from your 2nd…
cece
June 18, 2018
A Mix-and-Match Approach to Treating Non-Small-Cell Lung Cancer ResearchStories

A Mix-and-Match Approach to Treating Non-Small-Cell Lung Cancer

http://egfrcancer.org/wp-content/uploads/2018/03/Teri-Kennedy.jpg *** This article was first posted on www.curetoday.com*** During summer 2015, Teri Kennedy was at a yoga festival in Squaw Valley, California, when she started to wheeze and had trouble breathing. The inhaler her doctor gave her didn’t help. When the then 51-year-old from Sacramento returned home, she went…
cece
May 1, 2018